For how we live.
In 221 male childhood-cancer survivors, FSH levels during puberty tracked adult testicular function. Radiotherapy damage persisted into adulthood, while alkylating-chemotherapy effects often recovered.
Among privately insured patients, 63% with IVF coverage had a baby within 2.5 years versus 53% without. The gap was driven mostly by covered patients starting more cycles — not a higher success rate per cycle.
A post hoc analysis of the BAMBINI trial asked whether losing too much weight could backfire on fertility in PCOS. It did not: every degree of weight loss was linked to a better chance of ovulating.
Injecting one sperm into each egg was meant for severe male-factor cases, yet clinics now use it widely. Pooling six randomised trials found no live-birth advantage over standard IVF when sperm is not the problem.
A European trial stopped early for futility: clinical pregnancy occurred in 15.7% of women given transdermal testosterone before IVF and 14.9% given placebo. The trial was funded by Ferring.
Popular extras like embryo genetic testing and endometrial scratching did not raise live-birth rates in their biggest randomised trials, and the UK regulator warns most patients need none of them.
A positive urine LH test was followed by ovulation within 48 hours in 92% of cycles in one study. But the tests predict ovulation rather than confirm it, and a surge can occur without an egg released.
It anchors every male-infertility evaluation, but its reference numbers come from a few thousand fertile men — and a normal result never rules fertility in or out.
Two systematic reviews point the same way: for the pill, IUDs, implants and most methods, about 8 in 10 women conceive within a year of stopping — similar to using no method at all.
In a study of 750 women, those with 'low' ovarian-reserve hormones were no less likely to conceive. Professional guidance says the test shouldn't be used to counsel women who aren't already infertile.
A review of 23 women's health apps found 87% shared user data with outside firms. The main US rule that covers them orders breach disclosure — it does not stop the sharing.
Consumer kits reliably estimate sperm concentration, and a smartphone assay matched lab classification ~98% of the time. But a normal count can't rule out the motility, shape and DNA problems a full analysis checks.
In a study of 543,167 cycles, calendar-based apps misclassified a fertile day as safe in two-thirds of cycles. Apps that track a real biological signal do better, but plain calendar apps remain the most common kind.
Whole-genome sequencing of 78 families put the figure at two mutations per year of paternal age. A cohort of 40 million US births found small increases in preterm birth and gestational diabetes.
Two randomised trials tested whether thyroid-hormone tablets help women who carry thyroid antibodies but have normal thyroid function and a history of miscarriage or infertility. Live-birth rates did not move.
The 2023 global guideline puts lifestyle first for everyone, letrozole first for fertility, and the pill for cycles and excess hair — while rating much of its own evidence low to moderate quality.
In two large clinics, the live birth rate per woman who returned to use her eggs was around 39-50% under 35 or 38, but far lower for older women — and most women who froze never came back to use them.
In modern couples timing intercourse, an estimated 18% of women aged 35-39 failed to conceive within a year — not one in three. The most alarming figures come from models, not from watching real couples try.
Wrist temperature rises after ovulation, not before it. That makes the watch's retrospective estimate biologically sound and useless as a way to predict the fertile window.
A network meta-analysis put pooled accuracy for the fertile window at 0.88, best in the three days around ovulation. A wrist-temperature study hit ovulation within three days about 78% of the time.
An 876-participant double-blind trial across 24 Chinese fertility centres nearly doubled serum 25-OHD in women with PCOS. Live births were 52.0% against 50.2% on placebo.
A double-blind trial randomised 750 women with polycystic ovary syndrome to one drug or the other. Letrozole produced more live births and more ovulation — and is now the guideline's first choice for fertility.